MORE►
Sulagna Bhattacharya
Ray Kaczmarek—the former CEO of Genezen—is an expert in gene therapy manufacturing with decades of experience leading operations, technology, and commercial supply strategies at pharmaceutical and biotech companies, Nanoscope said.
Dallas’ Nanoscope Therapeutics Hires Chief Technology, Manufacturing Officer
by Lance Murray | Dec 6, 2024
Ray Kaczmarek—the former CEO of Genezen—is an expert in gene therapy manufacturing with decades of experience leading operations, technology, and commercial supply strategies at pharmaceutical and biotech companies, Nanoscope said.
by Lance Murray |
May 17, 2024
Khandan Baradaran, PhD, was most recently VP of regulatory CMC at Ultragenyx Pharmaceutical, a biopharmaceutical company involved in the research and development of novel products for the treatment of rare and ultra-rare genetic diseases.
MORE►
by Lance Murray |
Apr 26, 2024
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye Hospital and co-director of the Wills Eye Hospital Retina Service.
MORE►
by Lance Murray |
Dec 8, 2023
Splendorio's more than 30 years of experience have been marked by extensive executive leadership in the ophthalmic industry, and he will support Nanoscope in reaching its strategic vision, the company said.
MORE►
Samuel Barone, M.D., is a former Federal Drug Administration official and leader in the pharmaceutical space.
Nanoscope Therapeutics Strengthens Clinical, Regulatory Expertise with Appointment of Chief Medical Officer
by Lance Murray | Sep 22, 2023
Samuel Barone, M.D., is a former Federal Drug Administration official and leader in the pharmaceutical space.
MORE►
by Dallas Innovates | Staff Report |
Apr 4, 2023
Dr. Zajicek and three other local biotech leaders—Sulagna Bhattacharya, CEO of Nanoscope Therapeutics; Gabby Everett, director of business operations and strategy at BioLabs Pegasus Park; and R.A. Session II, founder of Taysha Gene Therapies—discussed Dallas' biotech boom on a panel hosted by D CEO Healthcare.
MORE►
by Lance Murray |
Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE►
by Quincy Preston |
Mar 16, 2023
These standouts—startup founders, tech pioneers, educators, creators, social innovators, and business leaders—are transforming entire industries and making waves in their respective fields.
MORE►
Left: LinedanceAI co-founder Mohamed Elwazer; Center illustration: leonello/iStock; Right: Lantern Pharma CEO Panna Sharma
16 Biotech Companies in Dallas-Fort Worth ‘Putting the Tech in Bio’ to Drive Breakthroughs
by Dallas Innovates | Staff Report | Mar 1, 2023
Dallas-Fort Worth is well known for its tech expertise. Now it being recognized as the place where technology meets life science—a convergence that’s driving rapid growth in the biotech ecosystem. Leaders in the industry attribute this success to the unique convergence of the region’s exceptional tech talent pool and cutting-edge developments in life science....
MORE►
by Lance Murray |
Jan 11, 2023
Nanoscope Therapeutics Inc., a Dallas-based clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, has appointed Massoud Motamed, Ph.D., as vice president of quality.
Motamed brings nearly a decade of CGMP quality and compliance experience, including extensive experience in manufacturing and regulatory review of gene therapy products....
MORE►
by Dallas Innovates | Staff Report |
Sep 7, 2022
Every year, Tech Titans highlights the top movers and shakers in the North Texas technology ecosystem. Here are the finalists in 11 categories. Winners will be announced at the group's signature gala in October.
MORE►
[Image: Natali_Mis/istockphoto]
Bedford Biotech Restores “Meaningful Vision” in Blind Patients With Gene Therapy—and May Soon Go Public
by David Seeley | Jun 22, 2021
Nanoscope Therapeutics successfully treated 11 patients blinded by advanced retinitis pigmentosa (RP). A single intravitreal injection produced positive results that persisted through one year. The startup plans a Phase 2b trial this summer and plans to develop gene therapies to treat more common retinal diseases—like dry age-related macular degeneration.
MORE►
